HBVC基因启动子变异患者血清铁蛋白对干扰素治疗的影响

The effects of serum ferritin on interferon treatment in the core promotor gene mutants with chronic hepatitis B

  • 摘要: 目的: 探讨血清铁蛋白(SF)水平对有HBVC基因启动子(BCP)变异的患者干扰素疗效的影响。方法: 采用错配PCR RFLP技术检测HBVC基因启动子(BCP)变异,并检测其血清铁蛋白(SF)水平。结果: 随着病情的加重SF水平升高,且当SF≥ 30 0ng/ml时,可明显降低干扰素的疗效(P<0.0 5);发生BCP变异的病例,在干扰素治疗的过程中,SF水平升高的程度明显高于野生株组(P<0.0 0 1)。结论: 提示SF升高与肝功能损伤有着密切关系,SF水平升高可降低干扰素治疗的有效率,且有变异的病例可促使SF水平升高。

     

    Abstract: Objective: The effect of serum ferritin levels on interferon treatment with the core promotor gene mutants in chronic hepatitis B was observed in this study.Methods: The core promotor gene mutants with chronic hepatitis B were detected by using mismatch-PCR restriction fragment length polymorphism assay and the levels of serum ferritin with interferon treatment was also observed in this study.Results: It was showed that following the exaggeration of disease, the serum ferritin levels were raised and obviously decreased the effect of interferon therapy (P <0.05) when SF≥300 ng/ml. The serum ferritin levels in the mutant type group were significantly higher than that in the wild type group (P <0.001) in the route of interferon treatment. Conclusion: The results indicate that the level of serum ferritin has close relationships with the severity of liver diseases, height level of serum ferritin can decrease the effect of interferon treatment, and it can promote the levels of serum ferritin in these patients with the core promotor gene mutants.

     

/

返回文章
返回